TMO
Thermo Fisher ScientificBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes sustained instrument and consumables demand, continued margin expansion from operating leverage, and successful bolt‑on M&A driving multiple expansion toward the top of the analyst range.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -10.0.
What can break
Cyclical weakness in instrument orders and consumables demand
Momentum
24
Value
62
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $638.08 · Bull $787.50 · Bear $510.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $669.55
Why
Momentum24 · Δ7d +9.8
Value62 · Δ7d -0.3
Sentiment83 · Δ7d -10.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
24
34% active weight
Current posture
7d trendImproving
Δ7d
+9.8
Δ21d
+15.4
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.2
Sentiment
83
33% active weight
Current posture
7d trendSoftening
Δ7d
-10.0
Δ21d
-2.2
Why this grade
Composite grade B. Momentum 23.7 / Value 62.2 / Sentiment 82.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$183.6B
Beta
0.93
Shares Out
375.71M
P/E (TTM)
35.3
P/S (TTM)
5.25
P/FCF (TTM)
41.85
Rev YoY
+4.9%
EPS YoY
+0.7%
Gross Margin
+41.3%
Op Margin
+17.2%
Net Debt
$25.71B
Current Ratio
1.50
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology